India's Alembic Pharma gains after US FDA nod for cancer drug

Alembic Pharmaceuticals

30/06/2025 05:06

** Shares of Alembic Pharmaceuticals ALEM.NS rise 2.2% to 990 rupees

** Pharma co gets U.S. FDA's final approval for Doxorubicin Hydrochloride Liposome injection - used to treat certain types of cancer including ovarian cancer

** Avg rating on stock is "buy;" median PT is 988 rupees - data compiled by LSEG

** Stock down 7.2% YTD

 (Reporting by Aleef Jahan in Bengaluru)

 ((aleefjahan.cs@thomsonreuters.com))